Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by C WorldWide Group Holding A S

C WorldWide Group Holding A S raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 31.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,329 shares of the biotechnology company's stock after acquiring an additional 60,000 shares during the period. C WorldWide Group Holding A S owned 0.25% of Sarepta Therapeutics worth $15,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of SRPT. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after acquiring an additional 145 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in Sarepta Therapeutics by 22.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company's stock worth $773,000 after purchasing an additional 1,151 shares during the period. Corient Private Wealth LLC acquired a new stake in Sarepta Therapeutics during the 4th quarter worth $786,000. Xponance Inc. boosted its stake in Sarepta Therapeutics by 3.1% during the 4th quarter. Xponance Inc. now owns 18,713 shares of the biotechnology company's stock worth $2,275,000 after purchasing an additional 571 shares during the period. Finally, Teacher Retirement System of Texas boosted its stake in Sarepta Therapeutics by 19.1% during the 4th quarter. Teacher Retirement System of Texas now owns 25,412 shares of the biotechnology company's stock worth $3,090,000 after purchasing an additional 4,076 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $3.89 on Friday, reaching $18.08. 14,575,360 shares of the company's stock were exchanged, compared to its average volume of 2,441,528. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics, Inc. has a fifty-two week low of $13.97 and a fifty-two week high of $150.48. The business's 50-day moving average is $28.86 and its two-hundred day moving average is $69.08. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -6.72 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period last year, the business earned $0.73 EPS. The firm's revenue was up 80.2% on a year-over-year basis. As a group, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. William Blair reiterated a "market perform" rating on shares of Sarepta Therapeutics in a research note on Thursday. JPMorgan Chase & Co. reduced their price objective on shares of Sarepta Therapeutics from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price (down from $113.00) on shares of Sarepta Therapeutics in a report on Monday, June 16th. Piper Sandler downgraded shares of Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $70.00 to $36.00 in a report on Monday, June 16th. Finally, UBS Group dropped their target price on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of "Hold" and a consensus price target of $56.83.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.